drugset / Trial / NCT04233346
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
RandomizedSingle-groupOpen-labelTreatment
Summary
This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
Timeline
- Start
- 2020-07-09
- Primary completion
- 2022-07-22
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ponatinib | Small molecule | 30 mg | — |
| Subject | Ponatinib | Small molecule | 45 mg | — |